SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors react to a recent SEC filing regarding executive change-of-control agreements, which the community is widely interpreting as strategic preparation for a potential acquisition. This upward momentum is being amplified by significant short-covering pressure, as traders note high borrow fees and limited share availability ahead of an anticipated clinical trial data readout.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending as traders speculate on a potential structural memory supercycle, with extreme volatility and intense community debate over whether the stock is a long-term AI-driven winner or an overextended bubble following a massive surge. Investors are closely monitoring its performance relative to Micron Technology, fueling aggressive discussions between bulls chasing record highs and bears warning of an imminent pullback.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently a focal point for investors as the market anticipates the upcoming earnings report, with community discourse centered on potential turnaround signs, the impact of recent leadership changes, and heavy debate over whether the stock is an oversold value opportunity or a long-term trap. Investors are intensely focused on management's forward guidance and signals regarding market share competition, while sentiment remains deeply polarized between those accumulating shares at historic lows and skeptics expecting further downside.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing heightened social sentiment as traders highlight a structural squeeze setup characterized by a shrinking float from active share buybacks and high short interest. The community is closely watching key technical levels and institutional positioning, viewing the recent price action as a consolidation period before a potential breakout.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is facing significant community backlash as investors express deep frustration over long-term underperformance and a string of failed clinical trials, leading many to call for a change in leadership. While some market participants continue to accumulate shares based on an attractive dividend yield and potential pipeline value, sentiment remains heavily weighed down by institutional selling and a lack of conviction in the company's current strategic direction.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing extreme downward pressure and high volatility, fueled by significant short interest and negative sentiment regarding the software sector's recent performance. While retail investors are debating the stock's future amid institutional trimming and ongoing concerns over profitability, bulls are pointing to strong product adoption and upcoming catalysts like Config 2026 as potential turning points for a reversal.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and significant selling pressure, with the community actively debating whether the stock is undergoing a fundamental breakdown or presents a deep-value opportunity. Traders are heavily focused on the company's leveraged exposure to Bitcoin, with intense discussion surrounding potential dilution risks, legal investigations, and the sustainability of its treasury strategy.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate the impact of high-volume prediction markets and sports betting during major events like the World Cup, fueling discussions on whether these activities serve as a core revenue catalyst or a competitive threat. While some community members highlight the company's 50-state reach and strong handle metrics, others are focused on volatility, management share selling, and concerns over potential market cannibalization.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys stock is experiencing intense community-driven momentum fueled by a perceived short squeeze setup and activist investor speculation. Enthusiasts are actively coordinating to build a floor near current levels, treating the asset as a deeply undervalued play that is ripe for a significant rebound.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is seeing heightened community discussion as traders monitor the stock's consolidation and high cost-to-borrow, which many interpret as a potential setup for a short squeeze ahead of upcoming clinical data releases. Investors remain focused on the long-term potential of the Flamingo-01 trial and remain closely aligned with management's progress, viewing the recent share price drift and administrative filing delays as temporary hurdles rather than fundamental issues.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Bellus Health Inc

Bullish Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLUBellus Health Inc

Fundamentals

Latest BLU News